Posted inBiotechnology
Regeneron amplifies CHORD progression, sharing updated data on hearing loss gene therapy
Regeneron has posted updated clinical data on DB-OTO, providing more evidence of the gene therapy’s potential to treat a rare…
Posted inBiotechnology
AstraZeneca: Building a transparent pipeline from the ground up
Transparency is a word pharma companies often like to use, but, in practice, they rarely live up to the ideal.…
Posted inGenetics
Naked Mole-Rats’ Long Life Due to Better DNA Repair Mechanisms
Naked mole-rats are well known for both their wrinkly appearance and for their unexpectedly long lives. The source of this…
Posted inBiotechnology
Fortrea and Belite Bio talk innovation in ophthalmology trials
Sponsored By Fortrea Oct 13, 2025 8:00am Recruiting and retaining patients for ophthalmology clinical trials presents unique challenges, from strict…
Posted inBiotechnology
2 ex-Moderna leaders unveil $325M inaugural VC fund for platform biotechs
Two ex-Moderna leaders have hit a milestone in their new endeavor, closing a $325 million inaugural fund for their biotech…
Posted inBiotechnology
Chutes & Ladders—Former CBER chief Peter Marks leaps to Lilly
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…
Posted inBiotechnology
Bringing clinical trials to the community: a new model for precision enrollment
In the world of clinical trials, patient recruitment is an ongoing challenge. Despite technological advancements, sponsors often struggle to meet…
Posted inBiotechnology
Redefining Biotech: How AI and Real-World Data Power Patient-Centered Progress
The data and insights highlighted in the article are drawn from the Biotech Playbook for Progress, a comprehensive resource built from…
Posted inBiotechnology
Expedition resupplies for phase 2 COPD voyage with $165M series A
Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9.…
Posted inBiotechnology
Ono’s BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer.…